Agomelatine, melatonin and depressive disorder

Bibliography

• Srinivasan V, DeBernardis D, Shillcut SD, Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012;21:1503-22
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Mori D, Early evening melatonin and S-20098 advance circadian phase and nocturnal melatonin regulation of core body temperature. Am J Physiol 1997;272:R1178-86
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2012;15:417-28
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH, Baldwin DS, Haddad PM, The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010;25:95-102
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010;8:287-304
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010;24:479-99
   PubMed Web of Science ®Google Scholar
• Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
   PubMed Web of Science ®Google Scholar
• DeBernardis D, Di Iorio G, Acciavatti T, The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011;10:119-32
   PubMed Web of Science ®Google Scholar
• Howland RH, A. Benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011;34:709-31
   PubMed Web of Science ®Google Scholar
• Norman TR. Dysfunctional circadian rhythms and mood disorders: Opportunities for novel therapeutic approaches In: Cryan JF, Leonard BE, editors. Depression: From psychopathology to pharmacotherapy. Volume 27 Modern Trends in Pharmacopychiatry, Basel, Krager; 2010. p. 32-52
   Google Scholar
• Duncan WC. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 1996;71:253-312
   PubMed Web of Science ®Google Scholar
• Gordijn MC, Beersma DG, Bouhuys AL, A longitudinal study of diurnal mood variation in major depression. J Affect Disord 1994;31:261-73
   PubMed Web of Science ®Google Scholar
• Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychophamacol 2008;23:571-85
   PubMed Web of Science ®Google Scholar
• Emens J, Lewy A, Kinzie JM, Circadian misalignment in major depressive disorder. Psychiatry Res 2009;168:259-61
   PubMed Web of Science ®Google Scholar
• McIntyre IM, Burrows GD, Norman TR. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatry 1986;24:108-12
   Web of Science ®Google Scholar
• Soria V, Martinez-Amoros E, Escaramis G, Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010;35:1279-89
   PubMed Web of Science ®Google Scholar
• Uz T, Ahmed R, Akhisaroglu M, Effects of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. Neuroscience 2005;134:1309-16
   PubMed Web of Science ®Google Scholar
• Campbell S, MacQueen G. The role of the hippocampus in the pathophysiology of depression. J Psychiatry Neurosci 2004;29:417-26
   PubMed Web of Science ®Google Scholar
• Tataroglu O, Aksoy A, Yilmaz A, Effect of lesioning the suprachiasmatic nuclei on behavioural despair in rats. Brain Res 2004;1001:118-24
   PubMed Web of Science ®Google Scholar
• Tuma J, Strubbe JH, Mocaer E, Anxiolytic-like action of the antidepressant agomelatine (S-20098) after a social defeat requires integrity of the SCN. Eur Neuropsychopharmacol 2005;15:545-55
   PubMed Web of Science ®Google Scholar
• Revell VL, Burgess HJ, Gazda CJ, Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. J Clin Endocrinol Metab 2006;91:54-9
   PubMed Web of Science ®Google Scholar
• Norman TR, Cranston I, Irons JA, Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2C antagonist, S32006. Eur J Pharmacol 2012;674:310-12
   Google Scholar
• Tardito D, Molteni R, Popoli M, Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol 2012;22:S482-6
   Web of Science ®Google Scholar
• Spadoni G, Bedini A, Rivara S, Melatonin receptor agonists: new options for insomnia and depression. CNS Neurosci Ther 2011;17:733-41
   PubMed Web of Science ®Google Scholar